|
|
|
|
|
|
|
|
|
|
RCT: L-carnitine supplementation shows no benefit for fatigue in cancer patients - NeLM
RCT: L-carnitine supplementation shows no benefit for fatigue in cancer patients
Reference:
J Clin Oncol published early online on 17 September 2012
Source:
J Clin Oncol
Date published:
18/09/2012 17:15
Summary
by:
Hina Radia
According to research published early online in the
Journal of Clinical Oncology, four weeks of L-carnitine supplementation
did not improve fatigue in patients with invasive malignancies and good
performance status.
A double-blind, placebo-controlled study was conducted to evaluate L-carnitine, a popular complementary medicine often used by cancer patients for the treatment of fatigue.
The study involved 376 patients randomised to receive treatment with either 2g per day of L-carnitine supplementation or placebo. The primary end point was the change in average daily fatigue from baseline to week 4 using the Brief Fatigue Inventory (BFI). The following results were reported:
• The primary outcome, fatigue, measured using the BFI, improved in both arms compared with baseline (L-carnitine: −0.96, 95% CI, −1.32 to −0.60; placebo: −1.11, 95% CI −1.44 to −0.78, p=0.57 – not statistically significant).
• Secondary outcomes, including fatigue measured by the Functional Assessment of Chronic Illness Therapy–Fatigue instrument, depression, and pain, did not show significant difference between arms.
• There were no statistically significant differences in incidence of adverse events reported across the two groups.
The researchers concluded that despite some of the limitations of the study, it appears that 2-g of L-carnitine supplementation per day does not improve symptoms of fatigue in cancer patients.
A double-blind, placebo-controlled study was conducted to evaluate L-carnitine, a popular complementary medicine often used by cancer patients for the treatment of fatigue.
The study involved 376 patients randomised to receive treatment with either 2g per day of L-carnitine supplementation or placebo. The primary end point was the change in average daily fatigue from baseline to week 4 using the Brief Fatigue Inventory (BFI). The following results were reported:
• The primary outcome, fatigue, measured using the BFI, improved in both arms compared with baseline (L-carnitine: −0.96, 95% CI, −1.32 to −0.60; placebo: −1.11, 95% CI −1.44 to −0.78, p=0.57 – not statistically significant).
• Secondary outcomes, including fatigue measured by the Functional Assessment of Chronic Illness Therapy–Fatigue instrument, depression, and pain, did not show significant difference between arms.
• There were no statistically significant differences in incidence of adverse events reported across the two groups.
The researchers concluded that despite some of the limitations of the study, it appears that 2-g of L-carnitine supplementation per day does not improve symptoms of fatigue in cancer patients.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.